Vitamin D and Depression in Adults: A Narrative Review of the Association and the Effects of Supplementation

Ishrath Tabassum

Department of Pharmacology, Samskruthi College of Pharmacy, Jawahar Lal Nehru, University, Hyderabad, Telangana, 500023, India

*Corresponding Author: Corresponding Author: Ishrath Tabassum, Samskruthi College of Pharmacy, Dept: Pharmacology, Jawahar Lal Nehru, University, Hyderabad, Telangana, 500023, India, Email id: tabassumishrath23@gmail.com

Abstract

Keywords: Vitamin D; 25-hydroxyvitamin D; Depression; Depressive symptoms; Mental health

Introduction

Depression places an enormous burden on individuals and health systems. The World Health Organization estimates that around 280 million people live with the condition, equating to roughly 5% of adults, and ranks it among the leading causes of years lived with disability worldwide [1]. Beyond its toll on mood and daily functioning, depression is closely tied to poorer physical health, reduced productivity, and elevated mortality, which is part of why researchers keep looking for modifiable contributors that might be addressed alongside established treatments.

Vitamin D has emerged as one such candidate. Although it is best known for its role in calcium balance and bone health, vitamin D behaves more like a hormone than a conventional micro nutrient, and deficiency is strikingly common, affecting a large share of the population in many regions because of limited sun exposure, dietary gaps, skin pigmentation, and indoor lifestyles [2]. Of particular interest to psychiatry, the receptors through which vitamin D acts, together with the enzyme that converts it to its active form, are found in brain regions involved in mood and emotion, including the prefrontal cortex, cingulate gyrus, and hippocampus [3]. This anatomical overlap offers a biologically plausible route by which vitamin D status could influence depression.

Several mechanisms have been proposed. Vitamin D appears to take part in the synthesis and regulation of monoamine neurotransmitters such as serotonin and dopamine, to modulate neuroinflammatory and immune signalling, and to support neurotrophic processes and calcium homeostasis that underpin healthy neuronal function [4,5]. Each of these pathways has independently been implicated in depression, so a shared reliance on adequate vitamin D provides a coherent, if still unproven, explanation for the associations seen in population studies.

The epidemiological literature has repeatedly linked low circulating vitamin D to depression: people with depression tend to have lower vitamin D concentrations, and those in the lowest vitamin D categories appear to carry a higher risk of depression in both cross-sectional and prospective designs [4,6]. The treatment picture is murkier. If deficiency were genuinely causal, correcting it ought to relieve symptoms, yet supplementation trials have produced conflicting results, and the reasons for the inconsistency are not fully settled. This review synthesizes the current evidence on both the association and the effect of supplementation, and considers why the trial findings diverge.

Literature Search

This is a narrative review. To identify relevant material, the Pub-med/MEDLINE, Scopus, and Google Scholar databases were searched using combinations of terms including "vitamin D", "25-hydroxyvitamin D", "calciferous", "depression", "depressive symptoms", and "major depressive disorder". Priority was given to systematic reviews, meta-analyses, and large observational studies and randomized controlled trials (RCTs) published in peer-reviewed, English-language journals, supplemented by foundational mechanistic and epidemiological references. Reference lists of key articles were also examined for additional sources. Because this is a narrative rather than a systematic review, the selection of sources was purposive and not intended to be exhaustive; no formal screening protocol, dual independent screening, or quantitative pooling of new data was undertaken. The principal evidence syntheses discussed are summarized in [Table 2].

Biological Plausibility: How Vitamin D Might Affect Mood

The case for a link between vitamin D and depression rests first on biology. Vitamin D receptors are expressed in mood-relevant brain regions, and the active hormone influences several systems that are also disrupted in depression [3]. Three pathways are most often highlighted [Table 1]. First, vitamin D appears to help regulate the synthesis of monoamine neurotransmitters, including serotonin and dopamine, whose dysregulation is central to most models of depression [5]. Second, it exerts anti-inflammatory and immunopathology effects; since elevated pro-inflammatory signaling is associated with depressive symptoms, adequate vitamin D may buffer this process [5]. Third, through its role in neurotrophic support and calcium homeostasis, vitamin D contributes to neuronal growth, survival, and signaling [3]. None of these mechanisms proves causation on its own, but together they make the observed associations biologically credible rather than coincidental.

Table 1: Proposed biological pathways linking vitamin D to mood regulation

Vitamin D Status and Depression: Observational Evidence

The observational evidence points consistently in one direction. In the most widely cited synthesis of observational studies, which pooled data from more than 31,000 participants, people with depression had meaningfully lower vitamin D concentrations than non-depressed compactors (standardized mean difference 0.60, 95% CI 0.23–0.97). The lowest vitamin D categories were associated with higher odds of depression in cross-sectional analyses (odds ratio 1.31, 95% CI 1.00–1.71) and a markedly higher hazard in prospective cohorts (hazard ratio 2.21, 95% CI 1.40–3.49) [4]. A later dose–response meta-analysis of prospective cohort studies in older adults reinforced the prospective signal. Pooling six cohorts and over 16,000 participants, it found that each 10-ng/mL increment in serum vitamin D was associated with roughly a 12% reduction in the risk of developing depression (hazard ratio 0.88, 95% CI 0.78–0.99), following an approximately linear gradient [6]. Both syntheses reported substantial statistical heterogeneity (I² of 54% and 79%, respectively), reflecting differences in populations, vitamin D thresholds, and the extent of adjustment for con-founders-something that tempers, but does not overturn, the overall pattern.

Vitamin D Supplementation and Depression: Interventional Evidence

Whether supplementation actually relieves depression is where the literature becomes genuinely mixed, and the way trials are designed seems to drive the disagreement. An early meta-analysis of RCTs in adults found no statistically significant benefit of supplementation on depressive symptoms; importantly, its authors were candid that the available trials were small, clinically heterogeneous, and often enrolled participants who were neither depressed nor vitamin D deficient at the outset-conditions under which any real effect would be hard to detect [7].

When attention narrows to people who are actually depressed, the picture shifts. A meta-analysis confined to clinically diagnosed major depression pooled four RCTs (948 participants) and found a clear, moderate improvement in depression scores favoring vitamin D (mean effect size 0.58, 95% CI 0.45–0.72) [8]. A more recent and larger synthesis echoed this pattern: across all adults the overall effect on depressive symptoms was small and not robust, but a statistically significant antidepressant effect emerged in the subgroup with diagnosed major depressive disorder [9]. Read together, these analyses suggest that any benefit of supplementation is concentrated in those who are clinically depressed, and plausibly in those who are deficient to begin with [Table 2].

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; SMD, standardized mean difference; OR, odds ratio; HR, hazard ratio; CI, confidence interval; RCT, randomized controlled trial; MDD, major depressive disorder; I², proportion of variation attributable to heterogeneity.

Table 2: Summary of the principal evidence syntheses discussed in this review

Reconciling the Evidence: Why the Trials Disagree

The striking feature of this literature is that a consistent observational association sits alongside inconsistent trial results. The most coherent explanation is not that one body of evidence is wrong, but that the trials have frequently tested the wrong people. Correcting a genuine deficiency in a symptomatic person is biologically very different from adding more vitamin D to someone who is already replete and well, and pooling both kinds of participant dilutes any real effect toward the null. This is exactly what the subgroup findings imply: supplementation helps in diagnosed major depression but does little in unelected community samples [7,9].

Specific design factors compound the problem. Dose and formulation varied widely between trials, as did treatment duration-some too short for a slow-acting biological effect to appear. Baseline vitamin D status was often unmeasured or unaccounted for, so participants who could not benefit because they were already sufficient were mixed with those who might. Differences in the depression instruments used, and in whether participants had sub clinical symptoms or a formal diagnosis, added further noise [8,9]. High statistical heterogeneity across the pooled analyses is a quantitative signal of these underlying differences.

Clinical Implications

For practice, the most defensible reading is cautious. Screening for and correcting vitamin D deficiency is inexpensive, low-risk, and justified for general health, and it is reasonable to regard it as a sensible adjunct in depressed patients who are also deficient. The evidence does not, however, support vitamin D as a stand-alone antidepressant or as a routine intervention for people with normal vitamin D levels. Where supplementation is considered in the context of mood disorders, directing it at genuinely deficient, clinically depressed individuals is most consistent with what the data show [8-10].

Limitations of the Evidence and Future Directions

Several limitations qualify these conclusions. Observational designs cannot exclude reverse causation-depression can reduce time outdoors, appetite, and activity, all of which lower vitamin D-or residual confounding by physical health, season, and socioeconomic status. The trial literature is limited by small samples, short follow-up, inconsistent dosing, and the frequent enrolment of non-deficient or non-depressed participants. As a narrative review, the present synthesis is also purposive rather than exhaustive and does not generate a new pooled estimate.

Future work should prioritize adequately powered RCTs that enrol adults who are both clinically depressed and vitamin D deficient, use standardized and sufficient dosing over an adequate duration, stratify by baseline status, and report validated depression outcomes consistently. Mendelian randomization studies could help disentangle the direction of causation, and dose–response trials would clarify whether a therapeutic threshold exists [6,10].

Conclusions

The weight of evidence indicates that low vitamin D status and depression go together: deficiency is consistently associated with a higher likelihood and severity of depressive symptoms across observational and prospective data. The therapeutic story is more nuanced. Supplementation appears to help people with diagnosed major depression—particularly when they are deficient-while offering little measurable benefit to unelected or already-replete adults. Current evidence therefore supports a strong association but not a proven causal, treatment-defining role for vitamin D. Correcting deficiency remains a reasonable, low-risk adjunct in depressed patients, but firmer treatment recommendations await larger, better-targeted, and more uniform randomized trials.

References

1. World Health Organization (2023). Depressive disorder (depression). WHO Fact Sheet.Geneva: World Health Organization.

2. Holick MF (2007). Vitamin D deficiency. N Engl J Med. 357:266–281.

3. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ (2005). Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. J Chem Neuroanat. 29:21–30.

4. Anglin RES, Samaan Z, Walter SD, McDonald SD (2013). Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry. 202:100–107.

5. Parker GB, Brotchie H, Graham RK (2017). Vitamin D and depression. J Affect Disord. 208:56–61.

6. Li H, Sun D, Wang A, Pan H, Feng W,et al. (2019). Serum 25-hydroxyvitamin D levels and depression in older adults: a dose–response meta-analysis of prospective cohort studies. Am J Geriatr Psychiatry. 27:1192–1202.

7. Gowda U, Mutowo MP, Smith BJ, Wluka AE, Renzaho AMN (2015). Vitamin D supplementation to reduce depression in adults: meta-analysis of randomized controlled trials. 31:421–429.

8. Vellekkatt F, Menon V (2019). Efficacy of vitamin D supplementation in major depression: a meta-analysis of randomized controlled trials. J Postgrad Med. 65:74–80.

9. Mikola T, Marx W, Lane MM, Hockey M, Loughman A,et al. (2023). The effect of vitamin D supplementation on depressive symptoms in adults: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 63:11784–11801.

10. Xie F, Huang T, Lou D, Fu R, Ni C, et al. (2022). Effect of vitamin D supplementation on the incidence and prognosis of depression: an updated meta-analysis based on randomized controlled trials. Front Public Health. 10:903547.